Enlivex Therapeutics Ltd.

Enlivex Therapeutics Ltd. is a clinical-stage company that develops innovative immunotherapies based on macrophage reprogramming. Macrophages are immune cells that can either promote or suppress inflammation and tissue repair, depending on their state. Enlivex aims to restore the balance of macrophages in diseases where they are out of sync, such as sepsis, COVID-19, and solid cancers.

The company was founded in 2005 as a spin-off from the Hebrew University of Jerusalem and is headquartered in Nes-Ziona, Israel. It is listed on Nasdaq under the ticker symbol ENLV and has a market cap of about $92.8 million as of May 2023.

Enlivex's vision is to establish new equilibriums that solve complex diseases by harnessing the power of macrophages. Its lead product candidate, Allocetra™, is a cell-based therapy that reprograms macrophages from a pro-inflammatory to an anti-inflammatory state, thereby enhancing their ability to resolve inflammation and promote tissue healing.

Allocetra™ is currently being tested in several clinical trials for different indications, including organ failure associated with sepsis, advanced-stage solid tumors with peritoneal metastases, and COVID-19. The company has received orphan drug designation from the FDA and the EU for sepsis and peritoneal carcinomatosis, as well as a special life-threatening regulation from the EU that could enable post-phase II marketing approval for sepsis.

Foundation: 2005

Headquarters: Nes Ziona, Israel

Website: https://www.enlivex.com/